D. Tumukunde

发表

Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa

P. Kaleebu, D. Pillay, C. Gale, 2006, AIDS.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data

P. Kaleebu, D. Pillay, C. Gilks, 2017, BMC Infectious Diseases.

Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial

A. Walker, C. Gilks, D. Gibb, 2012, PLoS medicine.

Pregnancy rates and outcomes among women on triple-drug antiretroviral therapy (ART) in the DART trial.

C. Gilks, D. Gibb, C. Kityo, 2009 .

Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults

C. Gilks, D. Gibb, F. Ssali, 2010, Antimicrobial Agents and Chemotherapy.

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

A. Breckenridge, P. Kaleebu, D. Pillay, 2010, Lancet.

High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy

A. Breckenridge, P. Kaleebu, D. Pillay, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

P. Easterbrook, A. Siika, A. Kambugu, 2014, The New England journal of medicine.

Sexual behaviour among persons living with HIV/AIDS in Kampala, Uganda.

F. Ssali, C. Kityo, P. Mugyenyi, 2010, East African medical journal.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial

A. Kambugu, J. V. van Oosterhout, N. Paton, 2016, Journal of acquired immune deficiency syndromes.

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda

D. Pillay, J. Kigozi, E. Katabira, 2014, The Journal of antimicrobial chemotherapy.

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial

A. Breckenridge, P. Kaleebu, D. Pillay, 2010, The Lancet.

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

P. Easterbrook, A. Siika, A. Kambugu, 2014, The New England journal of medicine.